Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026

Core Viewpoint - Bright Minds Biosciences Inc. is set to announce topline results for the Phase 2 trial of BMB-101 targeting drug-resistant Absence Seizures and Developmental and Epileptic Encephalopathy on January 6, 2026 [1]. Group 1: Company Overview - Bright Minds is a clinical-stage biotechnology company focused on developing highly selective 5-HT receptor agonists for neurological and psychiatric disorders [1][3]. - The company aims to address conditions with high unmet medical needs, including Rare Epilepsy, Prader-Willi Syndrome, Depression, and other CNS disorders [3]. - Bright Minds has developed a unique platform of highly selective serotonergic agonists, leading to a rich portfolio of new chemical entity (NCE) programs within neurology and psychiatry [4]. Group 2: Event Details - A conference call and live webcast will take place at 8:00 AM ET on January 6, 2026, to discuss the Phase 2 trial results [1]. - The event will include a discussion of the data followed by a Q&A session for participants [2]. - A replay of the webcast will be available on the company's website after the event [2].